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BACKGROUND. Preclinical data suggest that the combination of intravenous (i.v.)
paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has signifi-
cant activity in patients with advanced, hormone-refractory prostate carcinoma.
The authors conducted this clinical trial to evaluate the addition of carboplatin to
the three-drug combination of paclitaxel, estramustine, and etoposide (TEE).
METHODS. Twenty patients with carcinoma of the prostate that was progressing
despite hormone therapy were enrolled on this Phase II trial. Patients were treated
with oral estramustine, 280 mg three times daily, and oral etoposide, 50 mg/m2,
once daily on Days 1–7, with i.v. paclitaxel, 135 mg/m2, over 1 hour followed by
carboplatin (area under the curve, 5) on Day 2 of each 21-day treatment cycle.
Patients were evaluated for response after three cycles, and three additional cycles
were given to responding or stable patients.
RESULTS. Nineteen patients were evaluable for response, and 12 patients had
measurable disease at baseline. The measurable response rate was 58% (7 of 12
patients; 95% confidence interval [95% CI], 28 – 85%), and all of those were partial
responses. Eleven patients had decreases  50% from their baseline prostate
specific antigen levels during therapy, for a response rate of 58% (95% CI, 34 – 80%)
by this criterion. The median time to disease progression was 5.5 months, with a
median survival of 14.2 months. Major toxicities included Grade (according to
version 2 of the National Cancer Institute Common Toxicity Criteria) 4 neutropenia
in 4 patients, Grade 4 thrombocytopenia in 4 patients, and anemia  Grade 3 in 4
patients. One patient had a deep vein thrombosis.
CONCLUSIONS. The combination of TEEC was active in patients with hormone-
refractory prostate carcinoma. The regimen was tolerable, with primarily hemato-
logic toxicity. The addition of carboplatin to TEE did not appear to add to the
efficacy of the three-drug combination of antimicrotubule agents. Cancer 2003;98:
269 –76. © 2003 American Cancer Society.
KEYWORDS: hormone-refractory prostate carcinoma, clinical trial, paclitaxel, estra-
mustine, etoposide, carboplatin.
Adenocarcinoma of the prostate continues to be a major cause ofmorbidity and mortality in men. Although hormone therapy ini-
tially is highly effective in treating symptoms and lowering prostate
specific antigen (PSA) levels, the median length of response in men
with metastatic disease is in the range of 18 –24 months.1 Recent
studies have demonstrated that estramustine-based regimens have
significant activity in patients with advanced prostate carcinoma,
although a positive impact on overall survival has yet to be demon-
strated.2–5
Estramustine phosphate, a combination of estradiol and nitrogen
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mustard, has demonstrated effectiveness in several
models of prostate carcinoma and has synergy with
other antimicrotubule agents.6 Estramustine exerts its
cytotoxicity by binding directly both microtubule-as-
sociated proteins and tubulin.7 Preclinical models re-
veal that estramustine acts synergistically with etopo-
side at low levels in the Mat-LyLu (MLL) subline of
Dunning rat prostate adenocarcinoma cells and in an
in vivo model.8 Three Phase II studies have demon-
strated that the combination of estramustine and eto-
poside has a soft tissue response rate of 40 –50%, with
at least 50% of patients showing decreases  50% in
PSA levels compared with baseline levels.9 –11 The ad-
dition of estramustine to the vinca alkaloid, vinblas-
tine, has shown synergistic effects on antimitotic ac-
tivity in vitro.12,13 Three Phase II studies have
demonstrated that the combination has a soft tissue
response rate of 15– 40%, with 40 – 60% of patients
showing decreases  50% in PSA levels compared with
baseline levels.14 –16 With the development of the tax-
anes and their ability to stabilize microtubules irre-
versibly, in vitro studies again demonstrated a syner-
gistic effect when paclitaxel was used in combination
with estramustine on the DU145 prostate carcinoma
cell line.17 The synergistic effect was seen with both
wild type and estramustine-resistant sublines of
DU145. A Phase II trial combining estramustine and a
96-hour infusion of paclitaxel demonstrated that 4 of 9
patients with measurable disease had a response, and
 50% of patients had decreases  50% in PSA levels
compared with baseline levels.6
Given the potential effectiveness of estramustine
in prostate carcinoma and its synergy with other an-
timicrotubule agents, we conducted a Phase II trial of
intravenous (i.v.) paclitaxel, oral estramustine, and
oral etoposide (TEE) in 37 patients with hormone-
refractory prostate carcinoma (HRPC).2 A response
rate of 45% (10 of 22 patients) was demonstrated in
patients with measurable disease. In addition, 65% of
patients had decreases  50% from their baseline PSA
levels. The therapy was tolerated well, with leukopenia
and anemia as the major toxicities. Serial measure-
ments of quality of life using the Functional Assess-
ment of Cancer Therapy-Prostate instrument showed
no significant change during therapy.
Based on these data, this three-drug combination
of antimicrotubule agents clearly has activity in HRPC.
Unfortunately, all of the patients eventually had dis-
ease progression, and most died of their prostate car-
cinoma. The activity of this regimen, however, makes
it a good starting point for the exploration of addi-
tional combinations that may capitalize on synergistic
interactions between the agents. Although carboplatin
has little or no evidence of activity as a single agent in
patients with prostate carcinoma,18 platinum com-
pounds are synergistic when combined with taxanes
in other tumor types.19 –21 Experiments using these
agents in vitro against the rat prostate carcinoma cell
line MLL and the human prostate carcinoma cell line
PC-3 demonstrated significant additive effects be-
tween the agents. The most significant growth inhibi-
tion was seen when all four agents were used together
(data not shown). These data prompted us to perform
preclinical in vivo testing of the agents alone and in
combination to determine their effect on prostate car-
cinoma cell growth. The results of these experiments
are shown in Figure 1. All of the agents inhibited MLL
cell growth significantly compared with control, with
etoposide demonstrating the most single-agent activ-
ity (P  0.001). The combination of estramustine and
etoposide inhibited tumor growth by 80% compared
with control (P  0.001). The addition of paclitaxel to
these two drugs resulted in growth inhibition of 85%
compared with control. Adding carboplatin to this
combination inhibited tumor growth by 96%, which is
significant compared with the next best combination
of estramustine, etoposide, and paclitaxel (P  0.05).
Similar observations led investigators at Memorial
FIGURE 1. The effect of drug treatment
on the growth of subcutaneously im-
planted Mat-LyLu cells. One million cells
were injected on Day 0. Animals were
killed and tumors were excised on Day 14.
Combinations of agents demonstrated a
wide range of activity. The combination of
estramustine (E), etoposide (V), paclitaxel
(T), and carboplatin (C) inhibited tumor
growth by 96% compared with the next
best combination of estramustine, etopo-
side, and paclitaxel (85% inhibition; P
 0.05). Bars indicate standard errors.
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Sloan Kettering Cancer Center (MSKCC) to combine
carboplatin with paclitaxel, and estramustine with the
estramustine given on a 5-day schedule.22 The overall
rate by PSA criteria was 67% in the 56 patients enrolled
on that dose escalation study. Based on these data, we
conducted the current Phase II trial to assess the ben-
efit of adding carboplatin to i.v. paclitaxel, with a
shortened course of oral estramustine and oral etopo-
side (TEEC). Efficacy and toxicity were the primary
endpoints of the study.
MATERIALS AND METHODS
Materials
Estramustine, etoposide, paclitaxel, and carboplatin
were obtained the hospital pharmacy. Each was stored
according to the manufacturer’s recommendations.
Estramustine was prepared as a stock solution of 100
mg/mL in 100% ethanol and was stored in a refriger-
ator.
Cell Cultures
The metastatic MLL prostate carcinoma subline of the
Dunning R-3327 rat prostate adenocarcinoma cell line
was obtained from Dr. John Isaacs (Johns Hopkins
University, Baltimore, MD). The cells were grown and
maintained in RPMI-1640 medium containing 10%
fetal bovine serum and 1% penicillin-streptomycin.
Animals
Male Copenhagen rats were obtained from Harlan
Sprague-Dawley (Indianapolis, IN). Methoxyflurane
(Pittman-Moore, Washington Crossing, NJ) was used
as inhalational anesthetic for injections.
Experimental Treatments
Animals (minimum, six per group) were injected with
1,000,0000 MLL cells (total volume, 0.1 mL) subcuta-
neously into the right flank on Day 0 based on a
protocol approved by the University of Michigan. Es-
tramustine was given intraperitoneally at a dose of 10
mg/kg on Days 4 –13. Etoposide was given at an intra-
peritoneal dose of 50 mg/kg on Days 4 –13. Paclitaxel
was given at a dose of 135 mg/M2 i.v. on Days 4 and 10.
Carboplatin was given at a dose of 400 mg/M2 i.v. on
Days 4 and 10. Tumor size was followed by caliper
measurement along two axes and by final tumor
weight on Day 14, when animals were killed by carbon
dioxide inhalation.
Patients
Eligible patients were required to have a histologic
diagnosis of adenocarcinoma of the prostate with pro-
gressive disease after receiving standard hormone
therapy. All patients who were treated previously with
an antiandrogen were required to undergo antiandro-
gen withdrawal. Patients were required to be off all
antiandrogens for at least 4 weeks with further evi-
dence of disease progression after cessation of the
antiandrogen. Patients also were required to have a
performance status of 0, 1, or 2 on the Zubrod scale
with a life expectancy  12 weeks and adequate bone
marrow (absolute neutrophil count [ANC]  1500/m3
and platelet count  100,000/m3), renal function (cre-
atinine  1.5 mg/dL), and hepatic function (bilirubin
 1.6 mg/dL and aspartate aminotransferase  3
times the upper limit of normal). Patients were re-
quired to have measurable soft tissue disease, or as-
sessable disease manifested as osseous disease with a
rising PSA level, or locally advanced disease with a
rising PSA level. Patients with any history of recent
myocardial infarction or ongoing ischemia requiring
antianginal agents, arrhythmia requiring antiarryth-
mics, or history of ischemic disease with documented
compromise of left ventricular function were excluded
from this study. Similarly, patients were excluded from
the study if they had uncontrolled hypertension,
known brain metastases, or spinal cord compression.
Patients were required to wait 4 weeks for study entry
after the completion of prior chemotherapy, radiation
therapy, or a change in hormone therapy. The study
was reviewed and approved by the University of Mich-
igan Institutional Review Board. All patients gave writ-
ten informed consent in accordance with federal,
state, and institutional guidelines.
Evaluations
Pretreatment evaluations consisted of a history and
physical examination with assessment of performance
status and laboratory studies, including complete
blood count, serum chemistry profile, PSA level, ra-
dionuclide bone scan, computed tomography (CT)
scans of the abdomen and pelvis, and chest X-ray.
Complete blood counts, including differential and
platelet counts, were monitored weekly, and chemis-
try profiles and PSA assessments were repeated every
3 weeks. Bone scans and CT scans were repeated every
9 weeks (3 treatment cycles) if they were positive at
baseline.
Treatment Regimen
All therapy in this study was administered in the out-
patient clinic. Estramustine was provided by Pharma-
cia and Upjohn (Kalamazoo, MI). Etoposide, pacli-
taxel, and carboplatin were supplied by Bristol-Myers
Squibb (Nutley, NJ). Treatment was comprised of oral
estramustine, 280 mg three times daily, and oral eto-
poside, 50 mg/m2 daily, on Days 1–7, and paclitaxel,
135 mg/m2 i.v., over 1 hour followed by carboplatin
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(area under the curve, 5) on Day 2 of each 21-day
treatment cycle. Patients initially received three cy-
cles, and three additional cycles were given to patients
who achieved a complete or a partial response or who
had stable disease. Before the administration of pac-
litaxel, patients were premedicated with dexametha-
sone at a dose of 20 mg orally 12 hours and 6 hours
pretreatment and immediately preinfusion with di-
phenhydramine, 50 mg i.v., and famotidine, 20 mg i.v..
Granisetron at a dose of 2 mg orally was given as a
standard antiemetic regimen for paclitaxel. Oral pro-
chlorperazine was used as a standard antiemetic reg-
imen during therapy with oral estramustine and eto-
poside.
All subsequent cycles of therapy required that tox-
icity resulting from the prior cycle had resolved and
that hematologic parameters had recovered to at least
meet the entry criteria (i.e., ANC  1500/m3 and plate-
let count  100,000/m3). Dose modifications for eto-
poside and paclitaxel were based on counts obtained
on Day 21 of each treatment cycle or the occurrence of
febrile neutropenia. If bone marrow suppression was
present on Day 21, then treatment was delayed until
the resolution of toxicity and was resumed with the
etoposide decreased to 50 mg per day alternating with
100 mg per day and paclitaxel reduced by 25% (for
patients with Grade 2 toxicity on Day 21) or etoposide
50 mg per day and a 50% dose reduction of paclitaxel
(for patients with bone marrow suppression  Grade
3 on Day 21). Febrile neutropenia resulted in the same
dose modification that was used for patients with
Grade 2 bone marrow suppression at Day 21. Estra-
mustine doses were not reduced for hematologic tox-
icity, and doses were held only in the event of nausea
and emesis that were not controlled by antiemetics.
Patients who were responding to therapy were
eligible for at least six cycles on this study. Patients
with evidence of response were monitored after com-
pletion of every third cycle and were eligible for re-
treatment until the point of disease progression. Pa-
tients who had not undergone an orchiectomy were
not maintained on a luteinizing hormone-releasing
hormone analog, because estramustine reliably results
in castrate levels of testosterone when given in this
fashion. At the end of treatment, patients who had not
undergone an orchiectomy were restarted on a lutein-
izing hormone-releasing hormone analog during the
monitoring period.
Toxicity and Response Criteria
Toxicity was graded according to the revised National
Cancer Institute Common Toxicity Criteria, version
2.0. Response was assessed using standard criteria for
measurable disease, if present. In the patients who
had elevations in serum PSA levels or bone-only dis-
ease, a complete response required the disappearance
of all measurable and nonmeasurable but assessable
lesions with a decrease in serum PSA levels to  1.0
ng/mL for at least 6 weeks’ duration. A partial re-
sponse was defined as a decrease  50% in any mea-
surable lesions and/or a decrease  50% in serum PSA
level without worsening of disease-related symptoms
for at least 6 weeks’ duration. Disease progression was
defined as the appearance of new signs and symptoms
of metastatic disease, new lesions, an increase in PSA
of 50% over baseline or nadir value, or an increase
 25% or  10 cm2 in the size of any measurable
lesion. All patients who did not meet these definitions
were considered to have stable disease.
Statistical Considerations
Statistical significance for the preclinical studies was
determined with the Student t tests and analyses of
variance using SigmaStat software (Jandel Scientific,
San Rafael, CA). The clinical trial was designed to
assess the efficacy of this combination with a primary
endpoint of tumor response. Response was assessed
using serum PSA levels and measurable disease, if
present. A 2-stage design was planned, with 22 re-
sponse-assessable patients accrued in the first stage.
The initial design required that at least 12 patients had
evidence of response for further enrollment. However,
as the trial progressed, 11 of the initial 20 patients had
evidence of response, and enrollment was closed due
to poor accrual. With 19 response-assessable patients,
a response rate of 70% could be distinguished from
50% with a power of 69% at the 10% significance level.
Response rates were assessed using PSA criteria for all
patients and classic criteria for patients with measur-
able disease. Patients who were not assessable for
response were included in the denominator unless
stated otherwise, providing a conservative estimate.
Estimates of response duration and overall survival
were obtained using the Kaplan–Meier method. Time
to disease progression was measured from the initia-
tion of therapy to the date of treatment failure. Treat-
ment failure included an increase in PSA of at least
50% more than the nadir value, progression of disease
by standard clinical criteria, or the institution of addi-
tional therapy for prostate carcinoma. The date of
treatment failure was defined as the date of first oc-
currence of any of these events; otherwise, the patient
was censored at the time of the last PSA measurement.
Survival was measured from initiation of therapy to
death, or the patient was censored at the date of last
follow-up.
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RESULTS
Between September 1997 and April 2000, 20 patients
were enrolled onto this Phase II study. All patients
developed disease progression on at least one hor-
mone therapy regimen in addition to antiandrogen
withdrawal (Table 1). Twelve patients had 1 form of
hormone therapy, with 8 patients receiving 2 or 3
 hormone therapies each. A total of 12 patients had
received chemotherapy prior to enrolling on this study
(8 patients had received 1 prior chemotherapy regi-
men, and 4 patients had received 2 prior chemother-
apy regimens). Two patients had received estramus-
tine and etoposide when they developed a rising PSA
level without evidence of metastases, and one patient
had received weekly paclitaxel with estramustine for
hormone-refractory disease. The other patients were
treated with cyclophosphamide and prednisone (six
patients), mitoxantrone and prednisone (three pa-
tients) and the oral 5-flourouracil analog UFT (two
patients), which was available previously as a study
regimen at our institution. Sixteen patients received
radiation therapy. Twelve patients (60%) had evidence
of measurable soft tissue disease, and 8 of those 12
patients also had evidence of bone involvement. The
remaining eight patients had bone-only disease.
A total of 86 cycles of therapy were delivered, with
a range of 1– 6 cycles per patient. Nine patients com-
pleted the six cycles of therapy initially planned. Only
five patients required a dose reduction, but two pa-
tients were able to continue for the full six cycles.
Neutropenia was the most common hematologic tox-
icity, with nine patients experiencing toxicity  Grade
3 (Table 2). Six patients had thrombocytopenia
 Grade 3. Four patients developed both neutropenia
and thrombocytopenia  Grade 3. Four patients had
anemia  Grade 3. One patient developed a deep
venous thrombosis that was treated successfully with
anticoagulation, and another patient experienced
Grade 4 diarrhea. Only three patients developed Grade
3 nausea, and only one patient had Grade 3 emesis.
Myalgias and arthralgias were common and occurred
48 –72 hours after the administration of paclitaxel. In
addition, mild peripheral neuropathy was common.
The pattern of neuropathy and its transient nature
were typical for paclitaxel.
Nineteen patients were assessable for response
(Table 3). Seven of 12 patients with measurable dis-
ease had at least a partial response, for an overall
response rate of 58% (95% confidence interval [95%
CI],23 28 – 85%). Four of 12 patients with bidimension-
ally measurable disease were evaluable by physical
TABLE 1
Patient Characteristics
Characteristic No. of patients (%)
Total patients 20
No. evaluable for response 19 (95)

















One regimen 12 (60)
Two or more regimens 8 (40)
Prior chemotherapy
No regimens 8 (40)
One or two regimens 12 (60)
Prior radiation therapy 16 (80)









Deep vein thrombosis 1 0
Diarrhea 0 1
TABLE 3
Response by Measurable Disease and Prostate Specific Antigen
Criterion
Response




No. of patients 19 4 10 12
CR 0 (0) 3 (75) 1 (10) 3 (25)
PR 11 (58) 0 (0) 4 (40) 4 (33)
SD 8 (42) 1 (25) 5 (50) 5 (42)
PSA: prostate specific antigen; PE: physical examination; CT: computed tomography; CR: complete
response; PR: partial response; SD: stable disease.
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examination. Three of those four patients achieved a
complete response in their palpable lesions alone,
including a rectal mass, a sternal mass, and a supra-
clavicular lymph node. Of eight patients with measur-
able disease only on CT scans, one patient had a
complete response, and three patients had partial re-
sponses by that criterion alone.
All patients enrolled had measurable PSA levels at
baseline, with values ranging from 0.6 ng/mL to 783.8
ng/mL. One patient withdrew early and did not have a
PSA evaluation after his only cycle of therapy; thus,
response was assessed by PSA criteria in the remain-
ing 19 patients. Eleven patients (58%; 95% CI, 34 –
80%) had decreases  50% in PSA levels during ther-
apy for at least 6 weeks; 9 of those 11 patients had a
decreases  75%. All but two of those responding
patients completed six cycles of therapy.
The median time to disease progression for all
patients was 5.6 months (95% CI, 4.4 – 6.2 months),
and the longest was 18.4 months. The median survival
was 14.4 months (95% CI, 11.6 –28.0 months). At the
time of this analysis, 17 patients had died. Of those
who remain alive, one patient has been followed for
43.5 months.
Associations between measurable disease and
PSA response were evaluated. Seven patients had a
response in their bidimensionally measurable disease,
as noted above. Four of those seven patients had re-
ductions  50% in PSA levels from baseline. Of the
three patients who did not qualify for a PSA response,
one patient had a baseline PSA level of 1.3 ng/mL that
decreased to a nadir of 1.1 ng/mL, another patient had
a decline in PSA level of 42%, and the third patient had
a decline in PSA level of 60% but developed disease
progression within 6 weeks. Five patients had stable,
bidimensionally measurable disease. Four of those 5
patients also had reductions  50% in PSA levels from
baseline. None of the patients who had achieved a
response according to PSA criterion and measurable
disease had evidence of progression of the measurable
disease while their PSA was decreasing.
In patients who had only bone scan evidence of
disease, 3 of 3 patients (100%) who had not received
prior chemotherapy had reductions  50% in their
PSA levels. In contrast, only 1 of 4 patients (25%) with
bone-only disease who had received prior chemother-
apy had reductions  50% in their PSA levels. Four of
5 patients (80%) with bidimensionally measurable dis-
ease who had not received prior chemotherapy had a
soft tissue response, compared with only 3 of 7 pa-
tients (43%) who had received prior chemotherapy.
Overall, prior chemotherapy did not seem to in-
fluence the response to this regimen as measured by
PSA. Five of 8 patients (62%) who had no prior therapy
had reductions  50% in PSA levels compared with 6
of 11 patients (54%) who had received prior chemo-
therapy. When analyzed by evaluable disease, 2 of 5
patients (40%) with bidimensionally measurable dis-
ease who had no prior therapy had reductions  50%
PSA levels compared with 5 of 7 patients (71%) who
had received prior chemotherapy.
Prior chemotherapy also appeared to have no sig-
nificant effect on the amount of toxicity experienced
with this regimen, presumably due to cumulative
bone marrow toxicity. The rate of significant bone
marrow suppression ( Grade 3 neutropenia, throm-
bocytopenia, and anemia) was comparable between
patients who had no prior chemotherapy and patients
who had at least one prior course. Overall, 8 of 12
patients who had received prior chemotherapy and 7
of 8 patients who had not received prior chemother-
apy had bone marrow suppression  Grade 3. Grade 4
neutropenia and thrombocytopenia occurred in two
patients in each group.
DISCUSSION
Recent clinical trials of combination chemotherapy in
patients with HRPC have demonstrated that responses
can be obtained. Unfortunately, these responses typ-
ically have been of short duration, and no survival
benefit has been demonstrated with any of the com-
binations studied to date. Clearly, there is a need for
more effective therapies for patients with HRPC. We
previously demonstrated that the combination of TEE
had significant activity with a high response rate ac-
cording to both measurable disease and PSA criteria.2
With the success seen in other tumor models using the
combination of platinum compounds and taxanes,
and with preclinical data to support this combination
in prostate carcinoma cell lines, the current Phase II
clinical trial investigated the potential benefit of add-
ing carboplatin to TEE.
The TEEC combination showed significant activ-
ity in this largely pretreated patient population. The
rate of response in terms of measurable disease and
PSA criteria were not significantly different from the
prior trial with TEE alone. Although responses were
demonstrated in patients who had received multiple
hormone and chemotherapy regimens, the duration
of response was short, on the order of months. From
this clinical trial, it does not appear that carboplatin
adds significantly to the toxicity, response rate, or
duration of response of TEE.
The TEEC regimen generally was tolerated well,
with 45% of patients receiving all 6 cycles. Only 20% of
patients failed to receive at least 3 cycles of therapy.
The toxicity was primarily hematologic, with 20% of
patients experiencing Grade 4 neutropenia, Grade 4
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thrombocytopenia, or Grade 3 or 4 anemia. One pa-
tient developed a deep venous thrombosis. In general,
the toxicity was expected and was not out of propor-
tion to the addition of carboplatin. In addition, the
severity of toxicity did not seem to correlate with the
amount of prior chemotherapy.
The response rate by PSA criteria (58%) was com-
parable to that seen in other trials using combina-
tion chemotherapy with estramustine as well as
TEE.2,4,10,15,24 The measurable response rate was 58%:
again, comparable to the response rate seen with TEE.
In patients who had responses in bidimensionally
measurable disease, only four of seven patients had a
decline in PSA by at least 50%, although all had a
decrease in PSA. No patients with measurable disease
progressed while responding by PSA. A decline in PSA
with therapy, therefore, does appear to be associated
with response in measurable disease.
Overall, prior chemotherapy did not seem to af-
fect the rate of PSA response. When patients were
analyzed by response criteria, all patients with only
bone scan evidence of disease who had no prior che-
motherapy had a PSA response, compared with only
33% of patients who had received prior chemotherapy.
This finding likely is due to the small sample size;
because, when all patients with bone scan evidence of
disease were compared for PSA response, there was no
significant difference between those who had or had
not received prior chemotherapy. It also is possible
that the patients with bone-only disease may have had
a different inherent biology, compared with patients
who had additional soft tissue metastases, that made
them more responsive to chemotherapy.
Investigators at MSKCC performed a dose-escala-
tion trial in 56 patients with advanced prostate carci-
noma using a similar combination.22 Paclitaxel was
given weekly as 1-hour infusions of 60 –100 mg/m2
with carboplatin (area under the curve, 6 mg/mL-
minute every 4 weeks) and oral estramustine (10
mg/kg daily for 5 days), Those authors reported re-
sponse rates of 45% in patients with measurable dis-
ease and 67% (95% CI, 55–79%) by PSA criteria. Similar
to our trial, the duration of estramustine dosing was
reduced to limit toxicities. Despite this, 25% of their
patients developed thromboembolic disease. Addi-
tional Grade 3 or 4 adverse effects were limited to
hyperglycemia (38%) and hypophosphatemia (42%).
No significant bone marrow suppression or peripheral
neuropathy was seen. The overall response rate and
toxicities on the MSKCC trial were similar to those
seen on the current trial.
This trial was able to show that, although the
addition of carboplatin to TEE is tolerated, it does not
seem to add significantly to the response rates dem-
onstrated with TEE or other estramustine-based regi-
mens. This trial was hindered by slow accrual and was
halted prior to completing the planned enrollment. In
addition, the length of treatment of estramustine and
etoposide was shortened from 14 days in the original
regimen to 7 days, which may have decreased the
effectiveness of adding carboplatin to TEE.
Although the TEEC regimen had a reasonable re-
sponse rate, the duration of response was relatively
short. This is the typical pattern of response to che-
motherapy in patients with this disease. Almost all of
the responding patients progressed within weeks of
completing their sixth and final planned cycle of che-
motherapy. Subsequent therapy usually was unsuc-
cessful in providing further control of the disease, and
it is unknown whether continued therapy would have
been effective in maintaining the response. Such ther-
apy undoubtedly would have been of limited duration
due to cumulative bone marrow toxicity. It is clear that
few of the regimens currently in Phase II and III trials
result in long-term control of androgen independent
prostate carcinoma, suggesting that further explora-
tion of new agents, schedules of existing regimens,
and the timing of treatment is warranted. One poten-
tial approach is the use of regimens with documented
activity in advanced prostate carcinoma earlier in the
course of disease in patients who have a high likeli-
hood of recurrence. Studies of the approach are being
conducted now at several centers and are under con-
sideration in the cooperative group setting. Hopefully,
they will provide further insight that will improve the
care of patients with advanced prostate carcinoma.
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